Axsome Therapeutics (AXSM) Non-Current Deferred Tax Liability (2019)
Axsome Therapeutics (AXSM) posted Non-Current Deferred Tax Liability of $121875.0 for Q4 2019.
Powered by 
Analysis
Axsome Therapeutics (AXSM) Non-Current Deferred Tax Liability (2019) Analysis & Trends
Axsome Therapeutics has reported Non-Current Deferred Tax Liability for 1 years, with the latest figure at $121875.0 in Q4 2019.
- Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $121875.0 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $121875.0 (changed N/A YoY) and the FY2019 annual result came in at $121875.0, changed N/A from the prior year.
- Non-Current Deferred Tax Liability was little changed at $121875.0 in Q4 2019 per AXSM's latest filing.
- Over five years, Non-Current Deferred Tax Liability peaked at $121875.0 in Q4 2019 and troughed at $121875.0 in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Axsome Therapeutics | 10.75 Bn | 10.43 Bn | 204.81 Mn |